Financial Data and Key Metrics Changes - Insmed reported a strong performance in 2025, with revenue guidance for BRINSUPRI set at a minimum of $1 billion for 2026, reflecting confidence in market access and early launch performance [9][10] - The company anticipates total revenue in 2026 to be more than double that of 2025, driven by both BRINSUPRI and ARIKAYCE [10][37] - As of the end of 2025, Insmed had approximately $1.4 billion in cash, cash equivalents, and marketable securities, positioning the company well for future investments [40][41] Business Line Data and Key Metrics Changes - BRINSUPRI achieved $144.6 million in net revenue in its first full quarter, exceeding expectations and indicating a strong launch trajectory [12] - ARIKAYCE experienced significant growth, particularly in Japan with a 40% increase compared to 2024, contributing over a quarter of its global revenues [31] - The cost of product revenues for Q4 2025 was $44.2 million, or 16.8% of revenues, reflecting improved gross margin due to BRINSUPRI's contributions [45] Market Data and Key Metrics Changes - The total addressable market for BRINSUPRI in the U.S. is estimated at 500,000 diagnosed patients with non-CF bronchiectasis, with significant potential for expansion as more patients are identified [13][18] - The company is actively working to identify additional patients with undiagnosed bronchiectasis among the 32 million diagnosed with COPD or asthma in the U.S. [17][20] Company Strategy and Development Direction - Insmed aims to expand its leadership in bronchiectasis and NTM, with plans to accelerate the U.S. launch of BRINSUPRI while continuing to grow ARIKAYCE [7][8] - The company is pursuing additional DPP1 inhibitors for respiratory diseases, indicating a strategy to broaden its therapeutic offerings [48] - Insmed is focused on educating physicians about bronchiectasis to enhance patient identification and treatment [18][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow positivity without needing to raise additional capital, although they may seek capital for strategic opportunities [11][43] - The positive early feedback from physicians and patients regarding BRINSUPRI is expected to drive increased prescribing behavior in the coming quarters [23][81] - Management highlighted the importance of market access dynamics, noting that over 90% of targeted patient lives have access to BRINSUPRI reimbursement [25][28] Other Important Information - The company received orphan drug designation for TPIP for the treatment of pulmonary arterial hypertension, which could enhance its market position [32] - Insmed is evaluating several business development opportunities to expand its pipeline and support future growth [11][76] Q&A Session Summary Question: Expansion of BRINSUPRI's Total Addressable Market - Management acknowledged the potential for expanding BRINSUPRI's market by identifying patients with COPD or asthma who may have undiagnosed bronchiectasis [47] Question: Guidance for BRINSUPRI and Patient Behavior - Management provided insights into patient compliance and prescription dynamics, indicating strong metrics that support their revenue guidance [51][52] Question: Trends in Prescription and Business Development - Management confirmed strong initial performance and expressed confidence in the ongoing launch, while also discussing potential business development opportunities [54][57] Question: Depth of Prescribing and Education Efforts - Management noted that many physicians are initially prescribing BRINSUPRI to one patient, with expectations that positive experiences will lead to increased prescribing [78][81] Question: Ex-U.S. Contribution to Revenue Guidance - Management indicated that contributions from ex-U.S. markets for BRINSUPRI in 2026 will be minimal, with a focus on U.S. sales [71][72]

Financial Data and Key Metrics Changes - Insmed reported a strong performance in 2025, with revenue guidance for BRINSUPRI of at least $1 billion in 2026, reflecting confidence in market access and early launch performance [5][6][25] - The company anticipates total revenue in 2026 to be more than double that of 2025, indicating a significant growth trajectory [6][25] - As of the end of 2025, Insmed had approximately $1.4 billion in cash, cash equivalents, and marketable securities, positioning the company well for future investments [29][31] Business Line Data and Key Metrics Changes - BRINSUPRI launched in the U.S. with net revenue of $144.6 million in its first full quarter, exceeding expectations [7][20] - ARIKAYCE showed strong growth, particularly in Japan with a 40% increase compared to 2024, contributing significantly to global revenues [21][25] - The company is pursuing additional DPP1 inhibitors for respiratory diseases, indicating a strategy to expand its product portfolio [35] Market Data and Key Metrics Changes - The total addressable market for BRINSUPRI in the U.S. is estimated at 500,000 diagnosed patients with non-CF bronchiectasis, with significant potential for expansion as more patients are identified [8][10] - The company is actively working to identify additional patients with undiagnosed bronchiectasis among those with COPD and asthma, which could significantly increase the patient base for BRINSUPRI [12][13] Company Strategy and Development Direction - Insmed aims to accelerate the U.S. launch of BRINSUPRI while continuing to grow ARIKAYCE, focusing on expanding its clinical pipeline in respiratory, inflammation, immunology, and neurology [4][5] - The company is committed to pursuing first or best-in-class therapies within its target therapeutic areas, indicating a proactive approach to pipeline development [5][6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow positivity without needing to raise additional capital, although they may seek capital for strategic opportunities [6][31] - The positive early feedback from physicians and patients regarding BRINSUPRI is expected to drive further prescribing behavior, enhancing the launch's momentum [17][66] Other Important Information - The gross-to-net guidance for BRINSUPRI in 2026 is expected to be in the mid-20s to low 30s percentage range, reflecting favorable payer contracting dynamics [27][28] - The company is evaluating several business development opportunities to support pipeline expansion and value creation [6][31] Q&A Session Summary Question: Plans to develop other DPP1 inhibitors - Insmed intends to bring other DPP1s forward, including INS1033 for rheumatoid arthritis and inflammatory bowel disease, and is also advancing DPP1s for respiratory conditions [35] Question: Guidance for BRINSUPRI and patient behavior - Management is seeing metrics at or above targets, contributing to confidence in achieving at least $1 billion in revenue for BRINSUPRI [39] Question: Trends in scrip data and interest in business development - Management noted strong initial performance and is open to pursuing first or best-in-class compounds for business development [42][45] Question: Depth of prescribing and physician behavior - Physicians are initially prescribing BRINSUPRI to one or two patients, with expectations that positive experiences will lead to increased prescribing [66] Question: Ex-U.S. contribution to BRINSUPRI guidance - Ex-U.S. contributions for BRINSUPRI in 2026 are expected to be very small, with a focus on U.S. market dynamics [58]